XML 72 R54.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jul. 01, 2018 | Jul. 02, 2017 | Jul. 01, 2018 | Jul. 02, 2017
Sales by segment of business |  |  |  |
Sales | $ 20,830 | $ 18,839 | $ 40,839 | $ 36,605
Percent Change (as a percent) | 10.60% |  | 11.60% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 10,640 | 9,726 | $ 20,591 | 19,104
Percent Change (as a percent) | 9.40% |  | 7.80% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 10,190 | 9,113 | $ 20,248 | 17,501
Percent Change (as a percent) | 11.80% |  | 15.70% |
CONSUMER |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 3,504 | 3,478 | $ 6,902 | 6,706
Percent Change (as a percent) | 0.70% |  | 2.90% |
CONSUMER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,476 | 1,487 | $ 2,912 | 2,901
Percent Change (as a percent) | (0.70%) |  | 0.40% |
CONSUMER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 2,028 | 1,991 | $ 3,990 | 3,805
Percent Change (as a percent) | 1.90% |  | 4.90% |
CONSUMER | Baby Care |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 456 | 494 | $ 913 | 949
Percent Change (as a percent) | (7.70%) |  | (3.80%) |
CONSUMER | Baby Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 89 | 113 | $ 186 | 226
Percent Change (as a percent) | (21.20%) |  | (17.70%) |
CONSUMER | Baby Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 367 | 381 | $ 727 | 723
Percent Change (as a percent) | (3.70%) |  | 0.60% |
CONSUMER | Beauty |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,109 | 1,076 | $ 2,193 | 2,057
Percent Change (as a percent) | 3.10% |  | 6.60% |
CONSUMER | Beauty | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 637 | 649 | $ 1,248 | 1,216
Percent Change (as a percent) | (1.80%) |  | 2.60% |
CONSUMER | Beauty | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 472 | 427 | $ 945 | 841
Percent Change (as a percent) | 10.50% |  | 12.40% |
CONSUMER | Oral Care |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 393 | 394 | $ 772 | 756
Percent Change (as a percent) | (0.30%) |  | 2.10% |
CONSUMER | Oral Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 157 | 150 | $ 314 | 306
Percent Change (as a percent) | 4.70% |  | 2.60% |
CONSUMER | Oral Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 236 | 244 | $ 458 | 450
Percent Change (as a percent) | (3.30%) |  | 1.80% |
CONSUMER | OTC |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,066 | 1,006 | $ 2,138 | 2,019
Percent Change (as a percent) | 6.00% |  | 5.90% |
CONSUMER | OTC | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 454 | 432 | $ 919 | 909
Percent Change (as a percent) | 5.10% |  | 1.10% |
CONSUMER | OTC | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 612 | 574 | $ 1,219 | 1,110
Percent Change (as a percent) | 6.60% |  | 9.80% |
CONSUMER | Women's Health |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 280 | 276 | $ 523 | 518
Percent Change (as a percent) | 1.40% |  | 1.00% |
CONSUMER | Women's Health | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 4 | 3 | $ 7 | 6
Percent Change (as a percent) | 33.30% |  | 16.70% |
CONSUMER | Women's Health | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 276 | 273 | $ 516 | 512
Percent Change (as a percent) | 1.10% |  | 0.80% |
CONSUMER | Wound Care/Other |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 200 | 232 | $ 363 | 407
Percent Change (as a percent) | (13.80%) |  | (10.80%) |
CONSUMER | Wound Care/Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 135 | 140 | $ 238 | 238
Percent Change (as a percent) | (3.60%) |  | 0.00% |
CONSUMER | Wound Care/Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 65 | 92 | $ 125 | 169
Percent Change (as a percent) | (29.30%) |  | (26.00%) |
PHARMACEUTICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 10,354 | 8,635 | $ 20,198 | 16,880
Percent Change (as a percent) | 19.90% |  | 19.70% |
PHARMACEUTICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 5,899 | 5,010 | $ 11,253 | 9,882
Percent Change (as a percent) | 17.70% |  | 13.90% |
PHARMACEUTICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 4,455 | 3,625 | $ 8,945 | 6,998
Percent Change (as a percent) | 22.90% |  | 27.80% |
PHARMACEUTICAL | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 3,338 | 2,959 | $ 6,380 | 5,889
Percent Change (as a percent) | 12.80% |  | 8.30% |
PHARMACEUTICAL | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 2,317 | 2,101 | $ 4,317 | 4,224
Percent Change (as a percent) | 10.30% |  | 2.20% |
PHARMACEUTICAL | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,021 | 858 | $ 2,063 | 1,665
Percent Change (as a percent) | 19.00% |  | 23.90% |
PHARMACEUTICAL | Immunology | REMICADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,320 | 1,530 | $ 2,709 | 3,202
Percent Change (as a percent) | (13.70%) |  | (15.40%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 918 | 1,064 | $ 1,834 | 2,246
Percent Change (as a percent) | (13.70%) |  | (18.30%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 104 | 127 | $ 246 | 292
Percent Change (as a percent) | (18.10%) |  | (15.80%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 298 | 339 | $ 629 | 664
Percent Change (as a percent) | (12.10%) |  | (5.30%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 548 | 439 | $ 1,066 | 867
Percent Change (as a percent) | 24.80% |  | 23.00% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 274 | 230 | $ 498 | 459
Percent Change (as a percent) | 19.10% |  | 8.50% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 274 | 209 | $ 568 | 408
Percent Change (as a percent) | 31.10% |  | 39.20% |
PHARMACEUTICAL | Immunology | STELARA® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,341 | 983 | $ 2,402 | 1,806
Percent Change (as a percent) | 36.40% |  | 33.00% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 919 | 680 | $ 1,571 | 1,227
Percent Change (as a percent) | 35.10% |  | 28.00% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 422 | 303 | $ 831 | 579
Percent Change (as a percent) | 39.30% |  | 43.50% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 129 | 7 | $ 203 | 14
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | 102 | 0 | 168 | 0
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | 27 | 7 | 35 | 14
PHARMACEUTICAL | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 849 | 792 | $ 1,679 | 1,541
Percent Change (as a percent) | 7.20% |  | 9.00% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 328 | 341 | $ 661 | 667
Percent Change (as a percent) | (3.80%) |  | (0.90%) |
PHARMACEUTICAL | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 521 | 451 | $ 1,018 | 874
Percent Change (as a percent) | 15.50% |  | 16.50% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 211 | 179 | $ 421 | 328
Percent Change (as a percent) | 17.90% |  | 28.40% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 15 | 17 | $ 29 | 29
Percent Change (as a percent) | (11.80%) |  | 0.00% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 196 | 162 | $ 392 | 299
Percent Change (as a percent) | 21.00% |  | 31.10% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 492 | 454 | $ 970 | 884
Percent Change (as a percent) | 8.40% |  | 9.70% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 277 | 278 | $ 550 | 537
Percent Change (as a percent) | (0.40%) |  | 2.40% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 215 | 176 | $ 420 | 347
Percent Change (as a percent) | 22.20% |  | 21.00% |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 146 | 159 | $ 288 | 329
Percent Change (as a percent) | (8.20%) |  | (12.50%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 36 | 46 | $ 82 | 101
Percent Change (as a percent) | (21.70%) |  | (18.80%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 110 | 113 | $ 206 | 228
Percent Change (as a percent) | (2.70%) |  | (9.60%) |
PHARMACEUTICAL | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,528 | 1,467 | $ 3,087 | 2,964
Percent Change (as a percent) | 4.20% |  | 4.10% |
PHARMACEUTICAL | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 639 | 620 | $ 1,263 | 1,284
Percent Change (as a percent) | 3.10% |  | (1.60%) |
PHARMACEUTICAL | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 889 | 847 | $ 1,824 | 1,680
Percent Change (as a percent) | 5.00% |  | 8.60% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 183 | 181 | $ 356 | 390
Percent Change (as a percent) | 1.10% |  | (8.70%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 68 | 76 | $ 134 | 184
Percent Change (as a percent) | (10.50%) |  | (27.20%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 115 | 105 | $ 222 | 206
Percent Change (as a percent) | 9.50% |  | 7.80% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 720 | 629 | $ 1,416 | 1,233
Percent Change (as a percent) | 14.50% |  | 14.80% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 438 | 387 | $ 838 | 759
Percent Change (as a percent) | 13.20% |  | 10.40% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / TRINZA® / TREVICTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 282 | 242 | $ 578 | 474
Percent Change (as a percent) | 16.50% |  | 21.90% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 188 | 207 | $ 384 | 414
Percent Change (as a percent) | (9.20%) |  | (7.20%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 80 | 91 | $ 162 | 186
Percent Change (as a percent) | (12.10%) |  | (12.90%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 108 | 116 | $ 222 | 228
Percent Change (as a percent) | (6.90%) |  | (2.60%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 437 | 450 | $ 931 | 927
Percent Change (as a percent) | (2.90%) |  | 0.40% |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 53 | 66 | $ 129 | 155
Percent Change (as a percent) | (19.70%) |  | (16.80%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 384 | 384 | $ 802 | 772
Percent Change (as a percent) | 0.00% |  | 3.90% |
PHARMACEUTICAL | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 2,456 | 1,727 | $ 4,767 | 3,321
Percent Change (as a percent) | 42.20% |  | 43.50% |
PHARMACEUTICAL | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,085 | 697 | $ 2,018 | 1,361
Percent Change (as a percent) | 55.70% |  | 48.30% |
PHARMACEUTICAL | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,371 | 1,030 | $ 2,749 | 1,960
Percent Change (as a percent) | 33.10% |  | 40.30% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 511 | 299 | $ 943 | 554
Percent Change (as a percent) | 70.90% |  | 70.20% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 298 | 212 | $ 562 | 413
Percent Change (as a percent) | 40.60% |  | 36.10% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 213 | 87 | $ 381 | 141
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 620 | 450 | $ 1,207 | 859
Percent Change (as a percent) | 37.80% |  | 40.50% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 250 | 202 | $ 477 | 392
Percent Change (as a percent) | 23.80% |  | 21.70% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 370 | 248 | $ 730 | 467
Percent Change (as a percent) | 49.20% |  | 56.30% |
PHARMACEUTICAL | Oncology | VELCADE® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 280 | 290 | $ 593 | 570
Percent Change (as a percent) | (3.40%) |  | 4.00% |
PHARMACEUTICAL | Oncology | VELCADE® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Oncology | VELCADE® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 280 | 290 | $ 593 | 570
Percent Change (as a percent) | (3.40%) |  | 4.00% |
PHARMACEUTICAL | Oncology | ZYTIGA® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 909 | 558 | $ 1,754 | 1,081
Percent Change (as a percent) | 62.90% |  | 62.30% |
PHARMACEUTICAL | Oncology | ZYTIGA® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 486 | 241 | $ 893 | 474
Percent Change (as a percent) |  |  | 88.40% |
PHARMACEUTICAL | Oncology | ZYTIGA® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 423 | 317 | $ 861 | 607
Percent Change (as a percent) | 33.40% |  | 41.80% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 136 | 130 | $ 270 | 257
Percent Change (as a percent) | 4.60% |  | 5.10% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 51 | 42 | $ 86 | 82
Percent Change (as a percent) | 21.40% |  | 4.90% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 85 | 88 | $ 184 | 175
Percent Change (as a percent) | (3.40%) |  | 5.10% |
PHARMACEUTICAL | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 665 | 85 | $ 1,250 | 85
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | 429 | 37 | 790 | 37
PHARMACEUTICAL | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | 236 | 48 | 460 | 48
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |  |  |
Sales by segment of business |  |  |  |
Sales | 311 | 45 | 582 | 45
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | 180 | 24 | 329 | 24
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | 131 | 21 | 253 | 21
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® |  |  |  |
Sales by segment of business |  |  |  |
Sales | 143 | 26 | 283 | 26
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | 71 | 2 | 139 | 2
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | 72 | 24 | 144 | 24
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |  |  |
Sales by segment of business |  |  |  |
Sales | 171 | 9 | 311 | 9
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | 155 | 8 | 279 | 8
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | 16 | 1 | 32 | 1
PHARMACEUTICAL | Pulmonary Hypertension | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales | 40 | 5 | 74 | 5
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | 23 | 3 | 43 | 3
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | 17 | 2 | 31 | 2
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,518 | 1,605 | $ 3,035 | 3,080
Percent Change (as a percent) | (5.40%) |  | (1.50%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,101 | 1,214 | $ 2,204 | 2,309
Percent Change (as a percent) | (9.30%) |  | (4.50%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 417 | 391 | $ 831 | 771
Percent Change (as a percent) | 6.60% |  | 7.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 388 | 413 | $ 803 | 844
Percent Change (as a percent) | (6.10%) |  | (4.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 97 | 142 | $ 229 | 308
Percent Change (as a percent) | (31.70%) |  | (25.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 291 | 271 | $ 574 | 536
Percent Change (as a percent) | 7.40% |  | 7.10% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 679 | 642 | $ 1,257 | 1,155
Percent Change (as a percent) | 5.80% |  | 8.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 679 | 642 | $ 1,257 | 1,155
Percent Change (as a percent) | 5.80% |  | 8.80% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 215 | 295 | $ 463 | 579
Percent Change (as a percent) | (27.10%) |  | (20.00%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 169 | 256 | $ 373 | 503
Percent Change (as a percent) | (34.00%) |  | (25.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 46 | 39 | $ 90 | 76
Percent Change (as a percent) | 17.90% |  | 18.40% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 236 | 255 | $ 512 | 502
Percent Change (as a percent) | (7.50%) |  | 2.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 156 | 174 | $ 345 | 343
Percent Change (as a percent) | (10.30%) |  | 0.60% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 80 | 81 | $ 167 | 159
Percent Change (as a percent) | (1.20%) |  | 5.00% |
MEDICAL DEVICES |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 6,972 | 6,726 | $ 13,739 | 13,019
Percent Change (as a percent) | 3.70% |  | 5.50% |
MEDICAL DEVICES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 3,265 | 3,229 | $ 6,426 | 6,321
Percent Change (as a percent) | 1.10% |  | 1.70% |
MEDICAL DEVICES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 3,707 | 3,497 | $ 7,313 | 6,698
Percent Change (as a percent) | 6.00% |  | 9.20% |
MEDICAL DEVICES | Diabetes Care |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 355 | 421 | $ 694 | 820
Percent Change (as a percent) | (15.70%) |  | (15.40%) |
MEDICAL DEVICES | Diabetes Care | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 129 | 160 | $ 246 | 314
Percent Change (as a percent) | (19.40%) |  | (21.70%) |
MEDICAL DEVICES | Diabetes Care | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 226 | 261 | $ 448 | 506
Percent Change (as a percent) | (13.40%) |  | (11.50%) |
MEDICAL DEVICES | Diagnostics |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 0 | 0 | $ 0 | 1
MEDICAL DEVICES | Diagnostics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | 0 | 0 | 0 | 0
MEDICAL DEVICES | Diagnostics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | 0 | 0 | 0 | 1
MEDICAL DEVICES | Interventional Solutions |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 667 | 573 | $ 1,307 | 1,122
Percent Change (as a percent) | 16.40% |  | 16.50% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 323 | 285 | $ 627 | 564
Percent Change (as a percent) | 13.30% |  | 11.20% |
MEDICAL DEVICES | Interventional Solutions | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 344 | 288 | $ 680 | 558
Percent Change (as a percent) | 19.40% |  | 21.90% |
MEDICAL DEVICES | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 2,262 | 2,293 | $ 4,512 | 4,568
Percent Change (as a percent) | (1.40%) |  | (1.20%) |
MEDICAL DEVICES | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,332 | 1,367 | $ 2,639 | 2,726
Percent Change (as a percent) | (2.60%) |  | (3.20%) |
MEDICAL DEVICES | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 930 | 926 | $ 1,873 | 1,842
Percent Change (as a percent) | 0.40% |  | 1.70% |
MEDICAL DEVICES | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 360 | 350 | $ 723 | 702
Percent Change (as a percent) | 2.90% |  | 3.00% |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 211 | 208 | $ 420 | 417
Percent Change (as a percent) | 1.40% |  | 0.70% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 149 | 142 | $ 303 | 285
Percent Change (as a percent) | 4.90% |  | 6.30% |
MEDICAL DEVICES | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 382 | 385 | $ 769 | 783
Percent Change (as a percent) | (0.80%) |  | (1.80%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 229 | 236 | $ 457 | 482
Percent Change (as a percent) | (3.00%) |  | (5.20%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 153 | 149 | $ 312 | 301
Percent Change (as a percent) | 2.70% |  | 3.70% |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 675 | 643 | $ 1,371 | 1,285
Percent Change (as a percent) | 5.00% |  | 6.70% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 394 | 390 | $ 801 | 781
Percent Change (as a percent) | 1.00% |  | 2.60% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 281 | 253 | $ 570 | 504
Percent Change (as a percent) | 11.10% |  | 13.10% |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 845 | 915 | $ 1,649 | 1,798
Percent Change (as a percent) | (7.70%) |  | (8.30%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 498 | 533 | $ 961 | 1,046
Percent Change (as a percent) | (6.60%) |  | (8.10%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 347 | 382 | $ 688 | 752
Percent Change (as a percent) | (9.20%) |  | (8.50%) |
MEDICAL DEVICES | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 2,515 | 2,384 | $ 4,938 | 4,655
Percent Change (as a percent) | 5.50% |  | 6.10% |
MEDICAL DEVICES | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,022 | 1,012 | $ 2,015 | 2,007
Percent Change (as a percent) | 1.00% |  | 0.40% |
MEDICAL DEVICES | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,493 | 1,372 | $ 2,923 | 2,648
Percent Change (as a percent) | 8.80% |  | 10.40% |
MEDICAL DEVICES | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,005 | 933 | $ 1,971 | 1,810
Percent Change (as a percent) | 7.70% |  | 8.90% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 402 | 400 | $ 795 | 792
Percent Change (as a percent) | 0.50% |  | 0.40% |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 603 | 533 | $ 1,176 | 1,018
Percent Change (as a percent) | 13.10% |  | 15.50% |
MEDICAL DEVICES | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,169 | 1,114 | $ 2,296 | 2,188
Percent Change (as a percent) | 4.90% |  | 4.90% |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 436 | 423 | $ 859 | 846
Percent Change (as a percent) | 3.10% |  | 1.50% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 733 | 691 | $ 1,437 | 1,342
Percent Change (as a percent) | 6.10% |  | 7.10% |
MEDICAL DEVICES | Surgery | SPECIALTY |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 341 | 337 | $ 671 | 657
Percent Change (as a percent) | 1.20% |  | 2.10% |
MEDICAL DEVICES | Surgery | SPECIALTY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 184 | 189 | $ 361 | 369
Percent Change (as a percent) | (2.60%) |  | (2.20%) |
MEDICAL DEVICES | Surgery | SPECIALTY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 157 | 148 | $ 310 | 288
Percent Change (as a percent) | 6.10% |  | 7.60% |
MEDICAL DEVICES | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 1,173 | 1,055 | $ 2,288 | 1,853
Percent Change (as a percent) | 11.20% |  | 23.50% |
MEDICAL DEVICES | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 459 | 405 | $ 899 | 710
Percent Change (as a percent) | 13.30% |  | 26.60% |
MEDICAL DEVICES | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 714 | 650 | $ 1,389 | 1,143
Percent Change (as a percent) | 9.80% |  | 21.50% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 844 | 753 | $ 1,651 | 1,436
Percent Change (as a percent) | 12.10% |  | 15.00% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 320 | 274 | $ 629 | 530
Percent Change (as a percent) | 16.80% |  | 18.70% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 524 | 479 | $ 1,022 | 906
Percent Change (as a percent) | 9.40% |  | 12.80% |
MEDICAL DEVICES | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 329 | 302 | $ 637 | 417
Percent Change (as a percent) | 0.00% |  | 0.00% |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 139 | 131 | $ 270 | 180
Percent Change (as a percent) | 0.00% |  | 0.00% |
MEDICAL DEVICES | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales | $ 190 | $ 171 | $ 367 | $ 237
Percent Change (as a percent) | 0.00% |  | 0.00% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueGoodsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_TRACLEERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SPECIALTYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |